Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
31 participants
INTERVENTIONAL
2024-06-11
2024-08-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FYB201 0.5 mg (0.05 mL of 10 mg/mL)
FYB201 provided in a pre-filled syringe (PFS), containing 0.5 mg of 10 mg/mL ranibizumab in 0.05 mL for intravitreal (IVT) administration
FYB201 0.5 mg (0.05 mL of 10 mg/mL)
IVT administration of FYB201 in a PFS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FYB201 0.5 mg (0.05 mL of 10 mg/mL)
IVT administration of FYB201 in a PFS
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Written and signed informed consent form (ICF) obtained before any study-related procedures are performed.
3. Have a confirmed diagnosis in one or both eyes of Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Macular Edema Following Retinal Vein Occlusion (RVO).
4. Qualifies for treatment with ranibizumab-eqrn according to the USPI.
5. Aged ≥18 years at the time of signing ICF.
6. If a subject is already on a ranibizumab regimen, timing of study participation should correlate with the regimen.
7. Male study subject (if his female spouse/partner is of childbearing potential) must confirm that he is using two acceptable methods for contraception (one of which must be a barrier method) starting at signing ICF and throughout the clinical study period and for 3 months after study drug administration. Male study subject should agree to inform his partner of participation in the study and the need to avoid pregnancy. Surgically sterilized and non-sexually active male subjects do not require additional use of contraception.
8. Male study subject agrees not to donate sperm starting from screening and throughout the clinical study period and for 3 months after study drug administration.
9. Female study subject must be categorized by at least one of the following:
* Not a Woman of Child-bearing Potential as described in Appendix 3 prior to signing ICF; or
* Surgically sterile or having undergone a hysterectomy as categorized in Appendix 3 at least 1 month prior to signing ICF; or
* Is using a highly effective contraception. All females of childbearing potential will be required to use highly effective contraception (as described in Appendix 3) starting at signing ICF and throughout the clinical study period and for 3 months after study drug administration.
10. Female study subject must not be lactating and must not be breastfeeding at screening until 3 months after study drug administration.
11. Female study subject must not donate ova starting at signing ICF and throughout the clinical study period and for 3 months after study drug administration.
Exclusion Criteria
2. Intraocular corticosteroid administration in the study eye within 30 day prior to Day 1.
3. The study subject has/had fever or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to Day 1.
4. The study subjects with a history or evidence of SARS-CoV-2 infection in the last month prior to signing ICF or having been in confirmed contact with SARS-CoV-2 positive patients in the last 2 weeks before dosing.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Formycon AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Campbell, California, United States
Research Site
Long Beach, California, United States
Research Site
Hagerstown, Maryland, United States
Research Site
Eugene, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FYB201-C3-02
Identifier Type: -
Identifier Source: org_study_id